Children with familial hypercholesterolemia are characterized by an inflammatory imbalance between the tumor necrosis factor α system and interleukin-10

Atherosclerosis

Volumn 214, Issue 1, 2011, Pages 163-168

  Narverud, Ingunn ^a,b,c   Ueland, Thor ^c,d   Nenseter, Marit S ^c,d   Retterstøl, Kjetil ^c   Telle Hansen, Vibeke H ^a,b   Halvorsen, Bente ^d,e   Ose, Leiv ^c   Aukrust, Pål ^c,d,e   Holven, Kirsten B ^a  

^a UNIVERSITY OF OSLO   (Norway)

^b OSLO METROPOLITAN UNIVERSITY   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e UNIVERSITY OF OSLO   (Norway)

Author keywords

Children; Hypercholesterolemia; Inflammation; TNF

Indexed keywords

INTERLEUKIN 10; LOW DENSITY LIPOPROTEIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADOLESCENT; ADULT; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; BLOOD LEVEL; CHILD; CONTROLLED STUDY; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HETEROZYGOTE; HUMAN; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCHOOL CHILD;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CHILD; FEMALE; HETEROZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; INFLAMMATION; INTERLEUKIN-10; MALE; MIDDLE AGED; RISK; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78650846820     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2010.10.002     Document Type: Article

References (36)

1. Brown M.S., Goldstein J.L. A receptor-mediated pathway for cholesterol homeostasis. Science 1986, 232:34-47.
2. Ose L. Diagnostic, clinical, and therapeutic aspects of familial hypercholesterolemia in children. Semin Vasc Med 2004, 4:51-57.
3. Marks D., Thorogood M., Neil H.A., Humphries S.E. A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis 2003, 168:1-14.
4. Hansson G.K. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695.
5. Young J.L., Libby P., Schonbeck U. Cytokines in the pathogenesis of atherosclerosis. Thromb Haemost 2002, 88:554-567.
6. Nathan C., Ding A. Nonresolving inflammation. Cell 2010, 140:871-882.
7. Aukrust P., Berge R.K., Ueland T., et al. Interaction between chemokines and oxidative stress: possible pathogenic role in acute coronary syndromes. J Am Coll Cardiol 2001, 37:485-491.
8. Waehre T., Damas J.K., Gullestad L., et al. Hydroxymethylglutaryl coenzyme a reductase inhibitors down-regulate chemokines and chemokine receptors in patients with coronary artery disease. J Am Coll Cardiol 2003, 41:1460-1467.
9. Holven K.B., Myhre A.M., Aukrust P., Hagve T.A., Ose L., Nenseter M.S. Patients with familial hypercholesterolaemia show enhanced spontaneous chemokine release from peripheral blood mononuclear cells ex vivo. Dependency of xanthomas/xanthelasms, smoking and gender. Eur Heart J 2003, 24:1756-1762.
10. Holven K.B., Damas J.K., Yndestad A., et al. Chemokines in children with heterozygous familiar hypercholesterolemia: selective upregulation of RANTES. Arterioscler Thromb Vasc Biol 2006, 26:200-205.
11. Ueland T., Vissers M.N., Wiegman A., et al. Increased inflammatory markers in children with familial hypercholesterolaemia. Eur J Clin Invest 2006, 36:147-152.
12. Waehre T., Halvorsen B., Damas J.K., et al. Inflammatory imbalance between IL-10 and TNFα in unstable angina potential plaque stabilizing effects of IL-10. Eur J Clin Invest 2002, 32:803-810.
13. Han X., Kitamoto S., Wang H., Boisvert W.A. Interleukin-10 overexpression in macrophages suppresses atherosclerosis in hyperlipidemic mice. FASEB J 2010.
14. Aukrust P., Ueland T., Muller F., et al. Elevated circulating levels of C-C chemokines in patients with congestive heart failure. Circulation 1998, 97:1136-1143.
15. Holven K.B., Scholz H., Halvorsen B., Aukrust P., Ose L., Nenseter M.S. Hyperhomocysteinemic subjects have enhanced expression of lectin-like oxidized LDL receptor-1 in mononuclear cells. J Nutr 2003, 133:3588-3591.
16. Aukrust P., Lien E., Kristoffersen A.K., et al. Persistent activation of the tumor necrosis factor system in a subgroup of patients with common variable immunodeficiency-possible immunologic and clinical consequences. Blood 1996, 87:674-681.
17. Tonstad S., Leren T.P., Sivertsen M., Ose L. Determinants of lipid levels among children with heterozygous familial hypercholesterolemia in Norway. Arterioscler Thromb Vasc Biol 1995, 15:1009-1014.
18. Rus H.G., Niculescu F., Vlaicu R. Tumor necrosis factor-alpha in human arterial wall with atherosclerosis. Atherosclerosis 1991, 89:247-254.
19. Ohta H., Wada H., Niwa T., et al. Disruption of tumor necrosis factor-alpha gene diminishes the development of atherosclerosis in ApoE-deficient mice. Atherosclerosis 2005, 180:11-17.
20. Xiao N., Yin M., Zhang L., et al. Tumor necrosis factor-alpha deficiency retards early fatty-streak lesion by influencing the expression of inflammatory factors in apoE-null mice. Mol Genet Metab 2009, 96:239-244.
21. Kleemann R., Zadelaar S., Kooistra T. Cytokines and atherosclerosis: a comprehensive review of studies in mice. Cardiovasc Res 2008, 79:360-376.
22. Koukkunen H., Penttila K., Kemppainen A., et al. C-reactive protein, fibrinogen, interleukin-6 and tumour necrosis factor-alpha in the prognostic classification of unstable angina pectoris. Ann Med 2001, 33:37-47.
23. Cesari M., Penninx B.W., Newman A.B., et al. Inflammatory markers and onset of cardiovascular events: results from the Health ABC study. Circulation 2003, 108:2317-2322.
24. El M.M., Beaudeux J.L., Drissi A., et al. Elevated serum levels of proinflammatory cytokines and biomarkers of matrix remodeling in never-treated patients with familial hypercholesterolemia. Clin Chim Acta 2006, 366:185-189.
25. Gokalp D., Tuzcu A., Bahceci M., Arikan S., Pirinccioglu A.G., Bahceci S. Levels of proinflammatory cytokines and hs-CRP in patients with homozygous familial hypercholesterolaemia. Acta Cardiol 2009, 64:603-609.
26. Aderka D., Engelmann H., Maor Y., Brakebusch C., Wallach D. Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med 1992, 175:323-329.
27. Ferrari R., Bachetti T., Confortini R., et al. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 1995, 92:1479-1486.
28. Aukrust P., Liabakk N.B., Muller F., Lien E., Espevik T., Froland S.S. Serum levels of tumor necrosis factor-alpha (TNFα) and soluble TNF receptors in human immunodeficiency virus type 1 infection-correlations to clinical, immunologic, and virologic parameters. J Infect Dis 1994, 169:420-424.
29. Mallat Z., Heymes C., Ohan J., Faggin E., Leseche G., Tedgui A. Expression of interleukin-10 in advanced human atherosclerotic plaques: relation to inducible nitric oxide synthase expression and cell death. Arterioscler Thromb Vasc Biol 1999, 19:611-616.
30. Pinderski Oslund L.J., Hedrick C.C., Olvera T., et al. Interleukin-10 blocks atherosclerotic events in vitro and in vivo. Arterioscler Thromb Vasc Biol 1999, 19:2847-2853.
31. Holm T., Ueland T., Halvorsen B., et al. A protective anti-inflammatory phenotype in high-risk individuals who do not develop coronary artery disease. J Am Coll Cardiol 2006, 47:1085-1086.
32. Terkeltaub R.A. IL-10: An "immunologic scalpel" for atherosclerosis?. Arterioscler Thromb Vasc Biol 1999, 19:2823-2825.
33. Leeuwenberg J.F., Jeunhomme T.M., Buurman W.A. Slow release of soluble TNF receptors by monocytes in vitro. J Immunol 1994, 152:4036-4043.
34. Yagi K., Hifumi S., Nohara A., et al. Difference in the risk factors for coronary, renal and other peripheral arteriosclerosis in heterozygous familial hypercholesterolemia. Circ J 2004, 68:623-627.
35. Smilde T.J., van W.S., Wollersheim H., Kastelein J.J., Stalenhoef A.F. Genetic and metabolic factors predicting risk of cardiovascular disease in familial hypercholesterolemia. Neth J Med 2001, 59:184-195.
36. de Sauvage Nolting P.R., Defesche J.C., Buirma R.J., Hutten B.A., Lansberg P.J., Kastelein J.J. Prevalence and significance of cardiovascular risk factors in a large cohort of patients with familial hypercholesterolaemia. J Intern Med 2003, 253:161-168.